Molly R Kelly-Goss1,2, Yousef R Badran1,2,3, Michael Dougan4,5. 1. Department of Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA. 2. Harvard Medical School, Boston, MA, 02115, USA. 3. Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA. 4. Harvard Medical School, Boston, MA, 02115, USA. mldougan@partners.org. 5. Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA. mldougan@partners.org.
Abstract
PURPOSE OF REVIEW: Immune checkpoint inhibitor (ICI) therapy revolutionized the treatment of multiple solid and hematologic malignancies. Yet, with it came profound inflammatory toxicities that mimic autoimmune diseases, termed immune-related adverse events (irAEs). Prominent among these is gastrointestinal inflammation, including a spectrum of gastritis, enteritis, and colitis. Here we synthesize an approach to immune checkpoint related enterocolitis (irEC) - including diagnostics and therapeutics - underpinned by new insights into the mechanism behind these phenomena. RECENT FINDINGS: This review presents updated insights on how to approach irEC, including novel approaches to selective immunosuppressive therapy, the role of fecal microbiota transplant, and the underlying cellular mechanisms of irEC. This review provides an update on irEC diagnosis and therapy, with considerations of new therapies and special patient populations. The field of gastrointestinal irAEs requires additional investigation, which will ultimately provide the tools required for patients to continue to receive life-saving ICI therapy.
PURPOSE OF REVIEW: Immune checkpoint inhibitor (ICI) therapy revolutionized the treatment of multiple solid and hematologic malignancies. Yet, with it came profound inflammatory toxicities that mimic autoimmune diseases, termed immune-related adverse events (irAEs). Prominent among these is gastrointestinal inflammation, including a spectrum of gastritis, enteritis, and colitis. Here we synthesize an approach to immune checkpoint related enterocolitis (irEC) - including diagnostics and therapeutics - underpinned by new insights into the mechanism behind these phenomena. RECENT FINDINGS: This review presents updated insights on how to approach irEC, including novel approaches to selective immunosuppressive therapy, the role of fecal microbiota transplant, and the underlying cellular mechanisms of irEC. This review provides an update on irEC diagnosis and therapy, with considerations of new therapies and special patient populations. The field of gastrointestinal irAEs requires additional investigation, which will ultimately provide the tools required for patients to continue to receive life-saving ICI therapy.
Authors: L Marthey; C Mateus; C Mussini; M Nachury; S Nancey; F Grange; C Zallot; L Peyrin-Biroulet; J F Rahier; M Bourdier de Beauregard; L Mortier; C Coutzac; E Soularue; E Lanoy; N Kapel; D Planchard; N Chaput; C Robert; F Carbonnel Journal: J Crohns Colitis Date: 2016-01-18 Impact factor: 9.071
Authors: Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: Pedro Berraondo; Ignacio Melero; Elisabeth Perez-Ruiz; Luna Minute; Itziar Otano; Maite Alvarez; Maria Carmen Ochoa; Virginia Belsue; Carlos de Andrea; Maria Esperanza Rodriguez-Ruiz; Jose Luis Perez-Gracia; Ivan Marquez-Rodas; Casilda Llacer; Martina Alvarez; Vanesa de Luque; Carmen Molina; Alvaro Teijeira Journal: Nature Date: 2019-05-01 Impact factor: 49.962
Authors: Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer Journal: N Engl J Med Date: 2021-03-04 Impact factor: 91.245
Authors: I Puzanov; A Diab; K Abdallah; C O Bingham; C Brogdon; R Dadu; L Hamad; S Kim; M E Lacouture; N R LeBoeuf; D Lenihan; C Onofrei; V Shannon; R Sharma; A W Silk; D Skondra; M E Suarez-Almazor; Y Wang; K Wiley; H L Kaufman; M S Ernstoff Journal: J Immunother Cancer Date: 2017-11-21 Impact factor: 13.751
Authors: Marnix H Geukes Foppen; Elisa A Rozeman; Sandra van Wilpe; Cindy Postma; Petur Snaebjornsson; Johannes V van Thienen; Monique E van Leerdam; Michel van den Heuvel; Christian U Blank; Jolanda van Dieren; John B A G Haanen Journal: ESMO Open Date: 2018-01-13